Skip to main content
CLPBY logo

Coloplast A/S (CLPBY) Stock: Price, Forecast & Analyst Target

Coloplast A/S (CLPBY) — price $7.28 (-0.82%), as of the Nov 19, 2026 trading session; market cap $16.4B.

Educational signal · not a buy or sell recommendation · How to read this

$7.28 −$0.06 (-0.82%) Market Cap $16.4B

Coloplast A/S · CLPBY · Healthcare · Medical - Instruments & Supplies

Coloplast A/S, founded in 1954 and headquartered in Humlebæk, Denmark, operates as a global developer and marketer of intimate healthcare products and services.

Price as of Nov 19, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • BAX · Baxter International Inc. · 57 /100
  • COO · The Cooper Companies, Inc. · 40 /100
  • RGEN · Repligen Corporation · 71 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$7.28
Change on the day-0.82%
52-week range$5.64–$9.29
Market capitalisation$16.4B—
Price / earnings (trailing)37.35
Shares traded on the day11.0K
Beta (volatility vs the S&P 500)0.53

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $5.75, high $9.52, latest $7.28. $9.52 $5.75 high $9.52 Oct 17, 2025 Nov 19, 2026 · $7.28 $9.09Oct 17, 2025$9.07Oct 31, 2025$9.18Nov 14, 2025$9.19Nov 28, 2025$8.82Dec 12, 2025$8.48Dec 26, 2025$8.81Jan 9, 2026$8.52Jan 23, 2026$7.81Feb 6, 2026$7.64Feb 20, 2026$7.24Mar 6, 2026$6.59Mar 20, 2026$6.87Apr 2, 2026$7.00Apr 17, 2026$6.27May 1, 2026$6.13May 15, 2026$6.20May 29, 2026$5.99Jun 12, 2026$5.91Jun 26, 2026$6.12Jul 10, 2026$6.19Jul 24, 2026$6.80Aug 7, 2026$6.88Aug 21, 2026$7.09Sep 4, 2026$6.45Sep 18, 2026$6.18Oct 2, 2026$7.08Oct 16, 2026$7.24Oct 30, 2026$7.49Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Coloplast A/S (CLPBY): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Favorable read

Read on: Nov 7, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Neutral
Revenue Growth Negative
Debt/Equity Negative
ROE Moderate
Gross Margin Moderate

Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Coloplast A/S (CLPBY), and what does it report?

Short answer

Coloplast A/S, founded in 1954 and headquartered in Humlebæk, Denmark, operates as a global developer and marketer of intimate healthcare products and services. Healthcare / Medical Instruments & Supplies SEC filing business address: Holtedam 1, DK-3050, G7, 00000. It employs 17,524 people and is led by Gavin Wood. In Q4 FY2026 it reported revenue of kr7.41B and net income of kr1.18B. The market values it at $16.4B.

2 · Latest results

What do the latest results show for Coloplast A/S (CLPBY)?

Short answer · as of

The most recent reported quarter, Q4 FY2026, carried revenue of kr7.41B. Against analyst estimates the company has EPS beat 4 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q4 FY2026kr7.41Bkr1.18Bkr0.52 (diluted)
Q3 FY2026kr7.48Bkr1.49Bkr0.65 (diluted)
Q2 FY2026kr7.20B-kr987M-kr0.44 (diluted)
Q1 FY2026kr7.04Bkr1.38Bkr0.61 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Coloplast A/S (CLPBY)?

Short answer · as of

The distress and quality screens read Altman Z 3.65 · Piotroski F 6. Trailing ratios: ROE 22.6% · ROA 6.6% · current ratio 0.74 · earnings yield 2.7% · free-cash-flow yield 5.8%.

4 · What to check next?

What should you watch next at Coloplast A/S (CLPBY)?

Short answer · as of

Current published price targets run low $7.38 · high $7.38 · consensus $7.38 · median $7.38 against a quoted price of $7.28 (as of Nov 19, 2026).

What the records here don't tell us

  • Detailed statement figures are not shown because their conversion to USD has not been verified.
  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • Fewer than two score snapshots exist, so no score trend is shown.

Checked against the records this page reads, on the dates shown above.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$7.38 – $7.38
Consensus target
$7.38
Median target
$7.38

Consensus record · Captured .

Measured against a quoted price of $7.28 (as of Nov 19, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held CLPBY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported CLPBY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Coloplast A/S (CLPBY)?

Read these with our analysis →

CLPBY Healthcare Stock FAQ

Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.

How do SenSura Mio and SpeediCath differ from Coloplast’s surgical urology products?

SenSura Mio ostomy appliances and SpeediCath catheters support ongoing condition management and repeat use. Surgical urology devices are tied more closely to procedures addressing stones, prostate conditions, voiding dysfunction, erectile dysfunction and incontinence.

Why can Coloplast’s organic growth exceed its reported growth?

Management expects currency movements to reduce reported revenue growth even while the underlying business expands organically. The same pressure is expected to weigh on reported operating margin.

What is the CLPBY stock price today?

The last price recorded for Coloplast A/S (CLPBY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the CLPBY price target?

The analyst consensus price target for Coloplast A/S (CLPBY), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 24 figures on this page — 1 from SEC filings and earnings calls, 18 from Financial Modeling Prep (FMP), 4 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • FAQ: How do SenSura Mio and SpeediCath differ from Coloplast’s surgical urology products?: Business description
  • FAQ: Why can Coloplast’s organic growth exceed its reported growth?: Management outlook — dated call excerpts
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.